Chonluten 20mg
Bronchial and Lung Mucosal Peptide Bioregulator
Chonluten is a Khavinson short peptide bioregulator (Lys-Glu-Asp) targeting bronchial and lung mucosal cells, supporting respiratory mucosa repair and normal pulmonary epithelial function.
Bronchial and Lung Mucosal Peptide Bioregulator
Organ-specific peptide for bronchial mucosa, supporting mucosal cell gene expression normalization and respiratory epithelial tissue health in pulmonary research.
As one of the most studied compounds in the recovery & healing research space, Chonluten has attracted sustained scientific interest across Pulmonary mucosal research, Respiratory tissue studies. Peer-reviewed evidence indicates that lung mucosal Khavinson bioregulator, which has positioned Chonluten as a reference standard for researchers exploring pulmonary mucosal research outcomes. The compound's selectivity and documented tolerability in preclinical models have contributed to a rapidly growing body of literature over the past decade.
Chonluten Documented Benefits: 1 Documented Mechanisms
Mucosal Repair
Normalizes gene expression in bronchial mucosal cells to support respiratory healing.
How Chonluten Works: Molecular Mechanism & Pathway
Short tripeptide bioregulator with bronchial mucosa tissue specificity for epigenetic gene expression modulation.
The 1 primary research pathways identified for Chonluten — Mucosal Repair — collectively point to a compound with pleiotropic activity across interconnected biological systems. Studies have further shown that short tripeptide for targeted bronchial tissue, reinforcing the mechanistic picture established in earlier cell-line work. Unlike single-pathway agents, Chonluten's broad receptor engagement profile continues to generate hypotheses for novel applications beyond its originally characterized use cases.
Research Protocols & Compound Combinations
Chonluten is routinely studied alongside TA-1 and VIP in recovery & healing-focused compound panels. Researchers investigating pulmonary mucosal research have found that pairing compounds with complementary receptor profiles can produce additive results while keeping individual doses within well-characterized ranges. Preliminary evidence that 20mg research format has informed several of these multi-compound protocol designs.
Purity, Testing & Research Grade Standards
All Chonluten research material offered through this catalog is manufactured under controlled conditions and independently verified by a third-party laboratory prior to release. Each lot undergoes High-Performance Liquid Chromatography (HPLC) analysis to confirm ≥98% purity, with identity confirmed via mass spectrometry. The accompanying Certificate of Analysis (CoA) documents the exact purity, molecular weight confirmation, and lot-specific testing date — data that should accompany any reproducible research protocol. Lyophilized powder formulation ensures maximum stability during shipping and storage at −20°C long-term or 4°C for short-term use.
◈ Key Highlights
- Lung mucosal Khavinson bioregulator
- Short tripeptide for targeted bronchial tissue
- 20mg research format
Ideal For
- Pulmonary mucosal research
- Respiratory tissue studies
Intended for laboratory use only. Not for human or animal consumption. Not FDA approved. Handle in appropriate lab settings only.
What the Research Shows
The following data points are derived from peer-reviewed preclinical and clinical studies on Chonluten. All studies cited in compound profiles are indexed in PubMed or published in peer-reviewed journals.
Lung mucosal Khavinson bioregulator
Short tripeptide for targeted bronchial tissue
20mg research format
Third-Party Verified Every Batch
Each vial of Chonluten is independently tested by a third-party laboratory before fulfillment. You receive the actual CoA (Certificate of Analysis) documentation with your order.
